Why this beaten-down ASX 200 stock can jump 24%

Goldman Sachs thinks this sold off stock could generate big returns for investors.

The James Hardie Industries plc (ASX: JHX) share price was sold off on Tuesday.

The building materials company's shares ended the day a sizeable 15% lower at $46.67.

Investors were hitting the sell button in response to the release of the ASX 200 stock's fourth quarter and full-year update.

James Hardie reported record fourth-quarter sales of US$1,004.9 million and record full-year sales of US$3,936.3 million. However, despite this strong top-line performance, its earnings fell short of expectations for the fourth quarter.

And putting further pressure on the ASX 200 stock was its guidance for FY 2025, which was well below consensus estimates.

A young man wearing a black and white striped t-shirt looks surprised.

Image source: Getty Images

Broker reaction

Analysts at Goldman Sachs have been looking over the results. They note that James Hardie's fourth-quarter profit and guidance for FY 2025 disappointed. The broker said:

4Q24 result slightly below GSe. 4Q24 underlying NPAT of US$174m was 2% below GSe/Visible Alpha consensus estimates of US$178m/177m. Within this, EBIT of US$233m was 2% below GSe with sales 1% above GSe. JHX had previously guided to group NPAT of US$165-185m.

FY25 guidance disappoints. JHX issued group adjusted net income guidance US$630-700m vs prior GSe at US$761m and consensus at $762m (i.e. 13% lower at the midpoint).

Is this ASX 200 stock of good value after the sell-off?

Despite the disappointment, Goldman remains positive on James Hardie and believes yesterday's selloff has created a buying opportunity for investors.

In response to the update, the broker has reiterated its buy rating on the company's shares with a reduced price target of $57.85 (from $61.65).

Based on its current share price of $46.67, this implies a potential upside of 24% for investors over the next 12 months.

To put that into context, a $10,000 investment would grow to become worth $12,400 if Goldman is on the money with its recommendation.

Why is Goldman staying bullish?

Goldman believes that the market is undervaluing the ASX 200 stock even after lowering its earnings estimates for the near term. It explains:

As a result of our earnings changes (partially offset by updated reference multiples), our DCF & EV/EBIT based TP declines 6% to A$57.85. Notwithstanding the forecast revisions we believe that the share price is capitalizing earnings levels that are below both FY25E GSe and (more meaningfully) FY26E levels.

We see upside from cyclical improvement and strategic execution against higher value product mix targets, which has scope to substantially improve group profitability.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Buy, hold, sell: Fortescue, Santos, CBA shares

Let's review some new expert ratings and insights on 3 ASX 200 heavyweights.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »

Woman tying up her shoelaces before a run.
Broker Notes

Buy, hold, sell: Coles, Wesfarmers, CSL shares

It's a new week and we've got new ratings from the experts.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »